Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.46 USD

26.46
1,365,663

+0.15 (0.57%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Brian Bolan headshot

Best Stocks For The Second Half of 2017

A look at some stocks that are expected to show some good growth in the back half of the year.

    AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

    AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

      Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session

      Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day

        Top Ranked Momentum Stocks to Buy for June 27th

        Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 27th:

          AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

          AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

            Exelixis's Cabometyx Positive for First-Line Kidney Cancer

            Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

              Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

              Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU

                Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).

                  Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report?

                  Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy

                    Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy

                      Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus

                      Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.

                        Play Potential Earnings Beat with These 5 Top-Ranked Stocks

                        Bet on these top-ranked stocks that have the potential to beat the earnings estimate.

                          Is Intercept (ICPT) Poised for a Beat This Earnings Season?

                          Is Intercept (ICPT) Poised for a Beat this Earnings Season?

                            Apple (AAPL) to Report Q2 Earnings: Is a Beat in Store?

                            Apple, Inc. (AAPL) is set to report its second-quarter fiscal 2017 results on May 2.

                              What to Expect from Quotient Technology (QUOT) Q1 Earnings?

                              Quotient Technology Inc. (QUOT) is set to report first-quarter 2017 results on May 2.

                                Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?

                                Insperity, Inc. (NSP) is set to report first-quarter 2017 results on May 1.

                                  Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?

                                  Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.

                                    Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis

                                    Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis

                                      Arpita Dutt headshot

                                      M&As, Pipeline Catalysts to Drive Pharma Sector

                                      The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.

                                        Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y

                                        Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.

                                          Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC

                                          Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC

                                            Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?

                                            The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.

                                              Tirthankar Chakraborty headshot

                                              4 Stocks to Buy with Superb Earnings Acceleration

                                              Earnings acceleration helps spot stocks that haven't caught the attention of investors yet, which once secured will invariably lead to a rally in the share price.

                                                Keryx (KERX) Q4 Earnings: What's in Store for the Stock?

                                                Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.

                                                  Radius Health (RDUS) Posts Wider Loss in Q4

                                                  Radius Health, Inc. (RDUS) posted a loss of $1.22 per share in the fourth quarter of 2016, compared with a loss of 77 cents per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.16.